Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety surveillance of Cervarix in healthy Filipino females aged 10 years and older
2017-000458-20Phase 4
- Sponsor
- GSK
- Start
- Nov 2017
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection and Cervical Cancer (CC), sponsored by GSK. Primary endpoints: Number of subjects with any unsolicited symptoms, Number of subjects with Grade 3 unsolicited symptoms and 2 more.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on 2017-000458-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000458-20.